Literature DB >> 18389263

Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.

K Markopoulou1, D W Dickson, R D McComb, Z K Wszolek, L Katechalidou, L Avery, M S Stansbury, B A Chase.   

Abstract

Individuals with familial Parkinson's disease (PD) due to a monogenic defect can show considerable clinical and neuropathological variability. To identify factors underlying this variability, histopathological analysis was performed in two clinically different A53T alpha-synuclein heterozygotes from Family H, a multigenerational alpha-synuclein A53T kindred. To determine whether additional genetic factors could contribute to phenotypic variability, Family H and another multigenerational A53T kindred were analyzed for parkin polymorphisms. We identified a previously described variant in parkin exon 4 associated with increased PD risk (S167N). The two A53T heterozygotes had markedly different neuropathology and different parkin genotypes: A N167 homozygote had early onset rapidly progressive disease, early dementia, myoclonus and sleep disorder, while a S167 homozygote had late onset, slowly progressive disease and late dementia. Both had brainstem, cortical, and intraneuritic Lewy bodies (LB). The N167 individual had widespread cortical neurofibrillary degeneration, while the S167 individual had only medial temporal lobe neurofibrillary degeneration. The N167 individual had severe neuronal loss in CA2 associated with Lewy neurites (LN), while the S167 individual had severe neuronal loss in CA1 associated with TDP-43 immunoreactive neuronal inclusions. These findings implicate TDP-43 in the pathology of familial PD and suggest that parkin may act as a modifier of the A53T alpha-synuclein phenotype of familial PD. Furthermore, they suggest a mechanism by which a rare genetic variant that is associated with a minor increase of PD risk in the heterozygous state may, in the homozygous state, exacerbate a disease phenotype associated with a highly penetrant dominant allele.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18389263      PMCID: PMC2728685          DOI: 10.1007/s00401-008-0372-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  46 in total

Review 1.  Genetic modifiers of vision and hearing.

Authors:  Neena B Haider; Akihiro Ikeda; Jürgen K Naggert; Patsy M Nishina
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

2.  Higher order arrangement of the eukaryotic nuclear bodies.

Authors:  I-Fan Wang; Narsa M Reddy; C-K James Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-02       Impact factor: 11.205

Review 3.  Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease.

Authors:  Melisa J Baptista; Mark R Cookson; David W Miller
Journal:  Neuroscientist       Date:  2004-02       Impact factor: 7.519

4.  PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.

Authors:  Anita L DeStefano; Mark F Lew; Lawrence I Golbe; Margery H Mark; Alice M Lazzarini; Mark Guttman; Erwin Montgomery; Cheryl H Waters; Carlos Singer; Ray L Watts; Lillian J Currie; G Frederick Wooten; Nancy E Maher; Jemma B Wilk; Kristin M Sullivan; Karen M Slater; Marie H Saint-Hilaire; Robert G Feldman; Oksana Suchowersky; Anne-Louise Lafontaine; Nancy Labelle; John H Growdon; Peter Vieregge; Peter P Pramstaller; Christine Klein; Jean P Hubble; Carson R Reider; Mark Stacy; Marcy E MacDonald; James F Gusella; Richard H Myers
Journal:  Am J Hum Genet       Date:  2002-03-27       Impact factor: 11.025

5.  Colocalization of tau and alpha-synuclein epitopes in Lewy bodies.

Authors:  Takashi Ishizawa; Petri Mattila; Peter Davies; Dengshun Wang; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2003-04       Impact factor: 3.685

Review 6.  Genotype-phenotype correlation: familial Parkinson disease.

Authors:  Hideo Mori; Nobutaka Hattori; Yoshikuni Mizuno
Journal:  Neuropathology       Date:  2003-03       Impact factor: 1.906

7.  Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.

Authors:  Paul T Kotzbauer; Benoit I Giasson; Alexxai V Kravitz; Lawrence I Golbe; Margery H Mark; John Q Trojanowski; Virginia M-Y Lee
Journal:  Exp Neurol       Date:  2004-06       Impact factor: 5.330

8.  The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

Authors:  Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

9.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.

Authors:  Matt Farrer; Jennifer Kachergus; Lysia Forno; Sarah Lincoln; Deng-Shun Wang; Mary Hulihan; Demetrius Maraganore; Katrina Gwinn-Hardy; Zbigniew Wszolek; Dennis Dickson; J William Langston
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

10.  Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.

Authors:  Annika F M Haywood; Brian E Staveley
Journal:  BMC Neurosci       Date:  2004-04-16       Impact factor: 3.288

View more
  38 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

Review 2.  Autosomal dominant Parkinson's disease caused by SNCA duplications.

Authors:  Takuya Konno; Owen A Ross; Andreas Puschmann; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2015-09-03       Impact factor: 4.891

3.  A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction.

Authors:  Andreas Puschmann; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Suzanne G Lindquist; Jørgen E Nielsen; Zbigniew K Wszolek; Matthew Farrer; Håkan Widner; Danielle van Westen; Douglas Hägerström; Katerina Markopoulou; Bruce A Chase; Karin Nilsson; Jan Reimer; Christer Nilsson
Journal:  Parkinsonism Relat Disord       Date:  2009-07-25       Impact factor: 4.891

4.  A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity.

Authors:  Parvoneh Poorkaj; Wendy H Raskind; James B Leverenz; Mark Matsushita; Cyrus P Zabetian; Ali Samii; Sophia Kim; Nayiry Gazi; John G Nutt; John Wolff; Dora Yearout; J Lynne Greenup; Ellen J Steinbart; Thomas D Bird
Journal:  Mov Disord       Date:  2010-07-30       Impact factor: 10.338

Review 5.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

6.  Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations.

Authors:  Hiroshige Fujishiro; Akiko Yamashita Imamura; Wen-Lang Lin; Hirotake Uchikado; Margery H Mark; Lawrence I Golbe; Katerina Markopoulou; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Am J Neurodegener Dis       Date:  2013-11-29

Review 7.  The neuropathology of genetic Parkinson's disease.

Authors:  Markos Poulopoulos; Oren A Levy; Roy N Alcalay
Journal:  Mov Disord       Date:  2012-03-26       Impact factor: 10.338

Review 8.  α-Synuclein and Parkinsonism: Updates and Future Perspectives.

Authors:  Kaie Rosborough; Neha Patel; Lorraine V Kalia
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

9.  The Chemical Molecule B355252 is Neuroprotective in an In Vitro Model of Parkinson's Disease.

Authors:  Nailya S Gliyazova; Gordon C Ibeanu
Journal:  Cell Mol Neurobiol       Date:  2015-12-09       Impact factor: 5.046

Review 10.  Pathomechanisms of TDP-43 in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Mikayla L Huntley; George Perry; Xinglong Wang
Journal:  J Neurochem       Date:  2018-02-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.